|
Valoración de DCF de Iovance BioTherapeutics, Inc. (IOVA)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Iovance Biotherapeutics, Inc. (IOVA) Bundle
¿Busca evaluar el valor intrínseco de Iovance BioTherapeutics, Inc.? Nuestra calculadora DCF (IOVA) integra datos del mundo real con características integrales de personalización, lo que le permite refinar sus pronósticos y tomar decisiones de inversión más informadas.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | .0 | .0 | .0 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 |
Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITDA | -189.4 | -250.9 | -328.3 | -374.8 | -427.4 | .7 | .7 | .7 | .7 | .7 |
EBITDA, % | 100 | 100 | 100 | 100 | -35948.86 | 60 | 60 | 60 | 60 | 60 |
Depreciation | 8.1 | 8.7 | 14.0 | 21.1 | 33.1 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 |
Depreciation, % | 100 | 100 | 100 | 100 | 2786.12 | 100 | 100 | 100 | 100 | 100 |
EBIT | -197.6 | -259.6 | -342.3 | -395.9 | -460.6 | .7 | .7 | .7 | .7 | .7 |
EBIT, % | 100 | 100 | 100 | 100 | -38734.99 | 60 | 60 | 60 | 60 | 60 |
Total Cash | 307.1 | 629.4 | 596.0 | 471.8 | 279.9 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .0 | .0 | .0 | .0 | .2 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 |
Account Receivables, % | 100 | 100 | 100 | 100 | 12.7 | 82.54 | 82.54 | 82.54 | 82.54 | 82.54 |
Inventories | .0 | .0 | .0 | .0 | 10.4 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 |
Inventories, % | 100 | 100 | 100 | 100 | 872.33 | 100 | 100 | 100 | 100 | 100 |
Accounts Payable | 15.6 | 13.5 | 27.4 | 26.6 | 33.1 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 |
Accounts Payable, % | 100 | 100 | 100 | 100 | 2785.79 | 100 | 100 | 100 | 100 | 100 |
Capital Expenditure | -6.9 | -46.8 | -37.6 | -20.4 | -22.3 | -.2 | -.2 | -.2 | -.2 | -.2 |
Capital Expenditure, % | 100 | 100 | 100 | 100 | -1874.68 | -20 | -20 | -20 | -20 | -20 |
Tax Rate, % | 0.7774 | 0.7774 | 0.7774 | 0.7774 | 0.7774 | 0.7774 | 0.7774 | 0.7774 | 0.7774 | 0.7774 |
EBITAT | -187.1 | -257.2 | -327.8 | -389.9 | -457.0 | .7 | .7 | .7 | .7 | .7 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -170.3 | -297.4 | -337.6 | -390.0 | -450.1 | -21.9 | 1.6 | 1.6 | 1.6 | 1.6 |
WACC, % | 7.13 | 7.13 | 7.13 | 7.13 | 7.13 | 7.13 | 7.13 | 7.13 | 7.13 | 7.13 |
PV UFCF | ||||||||||
SUM PV UFCF | -15.3 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 2 | |||||||||
Terminal Value | 33 | |||||||||
Present Terminal Value | 23 | |||||||||
Enterprise Value | 8 | |||||||||
Net Debt | -39 | |||||||||
Equity Value | 47 | |||||||||
Diluted Shares Outstanding, MM | 235 | |||||||||
Equity Value Per Share | 0.20 |
What You Will Receive
- Pre-Filled Financial Model: Iovance Biotherapeutics' actual data provides an accurate DCF valuation.
- Comprehensive Forecast Control: Modify revenue growth, profit margins, WACC, and other essential factors.
- Real-Time Calculations: Automatic updates allow you to view results instantly as you make adjustments.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
- Flexible and Reusable: Designed for adaptability, enabling repeated application for in-depth forecasts.
Key Features
- 🔍 Real-Life IOVA Financials: Pre-filled historical and projected data for Iovance Biotherapeutics, Inc. (IOVA).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Iovance’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Iovance’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Download: Obtain the pre-built Excel file containing Iovance Biotherapeutics, Inc. (IOVA) financial data.
- Customize: Modify projections, including revenue growth, EBITDA %, and WACC as needed.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various projections and analyze results immediately.
- Make Decisions: Leverage the valuation outcomes to inform your investment approach.
Why Choose This Calculator for Iovance Biotherapeutics, Inc. (IOVA)?
- User-Friendly Interface: Perfectly crafted for both novice and seasoned users.
- Customizable Inputs: Adjust parameters easily to tailor your financial analysis.
- Real-Time Feedback: Instantly observe changes in Iovance's valuation as you modify inputs.
- Pre-Configured Data: Comes with Iovance’s actual financial statistics for swift evaluations.
- Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.
Who Should Use This Product?
- Investors: Evaluate Iovance Biotherapeutics’ (IOVA) market potential before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation methodologies and assess financial forecasts.
- Startup Founders: Understand the valuation processes of innovative biotech firms like Iovance.
- Consultants: Create comprehensive valuation reports for biotech clients.
- Students and Educators: Utilize current data to learn and teach valuation strategies in the biotech sector.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Iovance Biotherapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Iovance Biotherapeutics, Inc. (IOVA).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.